Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuko Matsushima

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|July 3, 2026
Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future PathwaysYosuke Kobayashi, Nobuko Matsushima, Noriyuki Takai, et al.
Journal of Personalized Medicine|May 28, 2022
A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized TherapiesVictoria Serelli-Lee, Kazumi Ito, Akira Koibuchi, et al.
Clinical Pharmacology and Therapeutics|July 2, 2004
Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypesJohn J Lima, Nobuko Matsushima, Niranjan Kissoon, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 21, 2013
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitorJeanne Mendell, Hamim Zahir, Nobuko Matsushima, et al.
Thrombosis and Haemostasis|May 26, 2012
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsHamim Zahir, Nobuko Matsushima, Abdel-Baset Halim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2013
Alpha-amylase inhibitor, CS-1036 binds to serum amylase in a concentration-dependent and saturable mannerTomohiro Honda, Yoko Kaneno-Urasaki, Takashi Ito, et al.
Clinical Drug Investigation|July 29, 2024
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese VolunteersNobuko Matsushima, Sayori Shibata, Jocelyn H Leu, et al.
Platelets|June 14, 2006
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humansFumitoshi Asai, Joseph A Jakubowski, Hideo Naganuma, et al.
Platelets|June 14, 2006
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humansNobuko Matsushima, Joseph A Jakubowski, Fumitoshi Asai, et al.
British Journal of Clinical Pharmacology|November 2, 2006
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humansJoseph A Jakubowski, Nobuko Matsushima, Fumitoshi Asai, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|July 3, 2026
Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future PathwaysYosuke Kobayashi, Nobuko Matsushima, Noriyuki Takai, et al.
Journal of Personalized Medicine|May 28, 2022
A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized TherapiesVictoria Serelli-Lee, Kazumi Ito, Akira Koibuchi, et al.
Clinical Pharmacology and Therapeutics|July 2, 2004
Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypesJohn J Lima, Nobuko Matsushima, Niranjan Kissoon, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 21, 2013
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitorJeanne Mendell, Hamim Zahir, Nobuko Matsushima, et al.
Thrombosis and Haemostasis|May 26, 2012
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsHamim Zahir, Nobuko Matsushima, Abdel-Baset Halim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2013
Alpha-amylase inhibitor, CS-1036 binds to serum amylase in a concentration-dependent and saturable mannerTomohiro Honda, Yoko Kaneno-Urasaki, Takashi Ito, et al.
Clinical Drug Investigation|July 29, 2024
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese VolunteersNobuko Matsushima, Sayori Shibata, Jocelyn H Leu, et al.
Platelets|June 14, 2006
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humansFumitoshi Asai, Joseph A Jakubowski, Hideo Naganuma, et al.
Platelets|June 14, 2006
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humansNobuko Matsushima, Joseph A Jakubowski, Fumitoshi Asai, et al.
British Journal of Clinical Pharmacology|November 2, 2006
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humansJoseph A Jakubowski, Nobuko Matsushima, Fumitoshi Asai, et al.
Pageof 3